Published: 7 September 2017

Recent Approvals of Medicines Containing a New Active Ingredient

Prescriber Update 38(3): 44
September 2017

For period 16 April 2017 to 15 July 2017

Trade Name (active ingredient)* Dose form and strength Therapeutic area
Akynzeo (netupitant/palonosetron) Combination capsule 300 mg/0.5 mg Chemotherapy-induced nausea and vomiting
Ibrance (palbociclib) Capsule 75 mg, 100 mg and 125 mg Hormone-receptor positive, HER2-negative, advanced breast cancer
Idelvion (albutrepenonacog alfa) Powder for injection 250 IU, 500 IU, 1000 IU and 2000 IU Haemophilia B
Nucala (mepolizumab) Powder for injection 100 mg/mL Eosinophilic asthma
Ranexa (ranolazine) Modified release tablet 375 mg, 500 mg and 750 mg Angina

* New active ingredient shown in bold type
Not available

The data sheets for currently marketed prescription medicines are published on the Medsafe website (